About Nuvation Bio Inc.
https://www.nuvationbio.comNuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6.
CEO
David T. Hung
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 120
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
RBC Capital
Outperform
Wedbush
Outperform
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
FMR LLC
Shares:50.57M
Value:$319.1M
DECHENG CAPITAL LLC
Shares:25.95M
Value:$163.77M
BLACKROCK, INC.
Shares:24.6M
Value:$155.25M
Summary
Showing Top 3 of 218
About Nuvation Bio Inc.
https://www.nuvationbio.comNuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $13.12M ▲ | $66.2M ▲ | $-55.79M ▲ | -425.24% ▲ | $-0.16 ▲ | $-54.76M ▲ |
| Q2-2025 | $4.83M ▲ | $65.85M ▲ | $-59.01M ▼ | -1.22K% ▲ | $-0.17 ▼ | $-58.23M ▼ |
| Q1-2025 | $3.08M ▼ | $59.99M ▲ | $-53.24M ▼ | -1.73K% ▼ | $-0.16 ▼ | $-52.87M ▼ |
| Q4-2024 | $5.71M ▲ | $55.44M ▲ | $-49.45M ▼ | -865.79% ▲ | $-0.15 | $-49.14M ▼ |
| Q3-2024 | $727K | $47.31M | $-41.21M | -5.67K% | $-0.15 | $-40.93M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $549.04M ▼ | $601.56M ▼ | $275.68M ▲ | $325.88M ▼ |
| Q2-2025 | $607.72M ▲ | $647.23M ▲ | $274.32M ▲ | $372.91M ▼ |
| Q1-2025 | $461.68M ▼ | $492.49M ▼ | $73.03M ▼ | $419.46M ▼ |
| Q4-2024 | $502.69M ▼ | $540.63M ▼ | $76.84M ▲ | $463.79M ▼ |
| Q3-2024 | $549.13M | $571.58M | $68.86M | $502.71M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-55.79M ▲ | $-52.89M ▼ | $-96.62M ▼ | $501K ▼ | $-149.07M ▼ | $-52.9M ▼ |
| Q2-2025 | $-59.01M ▼ | $-48.18M ▼ | $54.88M ▲ | $193.42M ▲ | $199.99M ▲ | $-48.36M ▼ |
| Q1-2025 | $-53.24M ▼ | $-42.63M ▲ | $54.18M ▲ | $548K ▲ | $12.25M ▲ | $-42.7M ▲ |
| Q4-2024 | $-49.45M ▼ | $-46.3M ▼ | $51.77M ▲ | $-900K ▲ | $5.69M ▲ | $-46.29M ▼ |
| Q3-2024 | $-41.21M | $-31.09M | $29.12M | $-1.54M | $-4.25M | $-31.23M |
Revenue by Products
| Product | Q1-2025 | Q2-2025 |
|---|---|---|
 License | $0 ▲ | $0 ▲ |
 Product | $0 ▲ | $0 ▲ |
 Product Revenue | $0 ▲ | $0 ▲ |
 Royalty Revenue | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
 CHINA | $0 ▲ | $10.00M ▲ | $0 ▼ | $0 ▲ |
 JAPAN | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 UNITED STATES | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
David T. Hung
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 120
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
RBC Capital
Outperform
Wedbush
Outperform
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
FMR LLC
Shares:50.57M
Value:$319.1M
DECHENG CAPITAL LLC
Shares:25.95M
Value:$163.77M
BLACKROCK, INC.
Shares:24.6M
Value:$155.25M
Summary
Showing Top 3 of 218